Displaying 241 - 260 of 310
FTC Challenges Schering-Ploughs Acquisition of Organon BioSciences N.V.
Mylan Laboratories Inc. and E. Merck oHG., In the Matter of
FTC Challenges Mylan's Proposed Acquisition of Merck's Generic Subsidiary
FTC Approves Final Consent Order in Matter of Actavis/Abrika
Actavis Group hf. and Abrika Pharmaceuticals, Inc., In the Matter of
FTC Testifies Before U.S. Senate on Barriers to Entry of Generic Drugs
FTC Challenges Actavis Group's Proposed Acquisition of Abrika
Hospira, Inc., and Mayne Pharma Limited, In the Matter of
The consent order settles charges that Hospira Inc.’s proposed $2 billion acquisition of rival drug manufacturer Mayne Pharma Ltd. would likely reduce competition in the following products: hydromorphone hydrochloride (hydromorphone), nalbuphine hydrochloride (nalbuphine), morphine sulfate (morphine), preservative-free morphine, and deferoxamine mesylate (deferoxamine). In settling the Commission’s charges, the companies agreed to divest to Barr Pharmaceuticals, Inc. (Barr), within 10 days of the acquisition, Mayne’s rights and assets related to the relevant products.
FTC Testifies on Patent Reform Recommendations
FTC Challenges Hospira/Mayne Pharma Deal
Bureau of Competition Issues FY 2006 Summary of Pharmaceutical Company Settlement Agreements
Watson Pharmaceuticals, Inc. and Andrx Corporation., In the Matter of
A consent order settled charges that Watson Pharmaceuticals, Inc.’s proposed $1.9 billion acquisition of Andrx Corporation, would have likely led to competitive problems in the markets for 13 generic drug products. Watson was required to end its marketing agreements with Interpham Holdings, divest Andrx’s right to develop, make, and market generic extended release tablets that correct the effects of type 2 diabetes, and divest Andrx’s rights and assets related to the developing and marketing of 11 generic oral contraceptives.
There is a related federal proceeding and two related administrative proceedings:
FTC Approves Final Consent Order in Barr/Pliva Matter
Barr Pharmaceuticals, Inc., In the Matter of
The consent order settles charges that Barr Pharmaceutical, Inc.’s proposed acquisition of Pliva d.d for approximately $2.5 billion would have eliminated current or future competition between Barr and Pliva in certain markets for generic pharmaceuticals treating depression, high blood pressure and ruptured blood vessels, and in the market for organ preservation solutions. In settling the Commission’s charges, Barr is required to sell its generic antidepressant trazodone and its generic blood pressure medication triamterene/HCTZ. Barr also is required to divest either Pliva’s or Barr’s generic nimodipine for use in treating ruptured blood vessels in the brain. Finally, Barr is required to divest Pliva’s branded organ preservation solution Custodial.
FTC Challenges Terms of Watson Pharmaceuticals Acquisition of Andrx
Court Enters Final Order Settling FTCs Charges Against Warner Chilcott
Consumers Win as FTC Action Results in Generic Ovcon Launch
FTC Challenges Barrs Proposed Acquisition of Pliva
Bureau of Competition Issues FY 2005 Summary of Pharmaceutical Company Settlement Agreements
Displaying 241 - 260 of 310